|Toxiciy Grade:||5||City/State/Province:||Orlando, FL|
|Treatments:||Chemotherapy||Hospital:||M.D. Anderson Cancer Center Orlando|
This phase III study involved women with ovarian cancer who were divided into two separate treatment groups. Group A consisted of 417 patients with a median age of 60 years. Group B had 414 patients with a median age of 60 years.
Patients in Group A were treated with the chemotherapy agents gemcitabine and carboplatin.
Patients in Group B were treated with the chemotherapy agents paclitaxel and carboplatin.
There were 2 deaths in Group A due to infection and respiratory failure. In addition, 80.6% of patients had grade 3-4 neutropenia, 40% had grade 3-4 thrombocytopenia, and 27.4 % had grade 3-4 anemia.
There were 3 deaths in Group B due to infection, pneumonia, and pulmonary embolism. In addition, 78.7% of patients had grade 3-4 neutropenia and 51% had grade 2 or higher alopecia.
The median overall survival rates for groups A and B were 43.8 and 57.3 months, respectively.
This study was supported by the pharmaceutical company Eli Lilly.
Correspondence: Dr. Alan N. Gordon; email: email@example.com